Related Experiment Video

Updated: Jun 17, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pneumococcal vaccination: effective in children under the age of 2 years

    Prescrire International
    |December 24, 2009
    PubMed

    Insights

    Pneumococcal vaccination for young children in France has successfully reduced cases of pneumococcal meningitis and bloodstream infections (bacteraemia). This public health intervention demonstrates significant effectiveness in protecting the pediatric population.

    Area of Science:

    • Pediatric infectious diseases
    • Vaccinology
    • Public health surveillance

    Background:

    • Pneumococcal infections, including meningitis and bacteraemia, pose a significant threat to young children.
    • The introduction of pneumococcal conjugate vaccines (PCVs) aimed to reduce the burden of these invasive diseases.

    Purpose of the Study:

    • To evaluate the impact of childhood pneumococcal vaccination on the incidence of pneumococcal meningitis and bacteraemia in France.

    Main Methods:

    • Analysis of national surveillance data.
    • Comparison of incidence rates before and after the introduction of the vaccination program.
    • Focus on children under 2 years of age.

    Main Results:

    • A significant decline in the incidence of pneumococcal meningitis among children under 2 years was observed post-vaccination introduction.
    • Similarly, a notable decrease in pneumococcal bacteraemia was documented in the same age cohort.

    Conclusions:

    • Pneumococcal vaccination is highly effective in preventing invasive pneumococcal disease in young children in France.
    • The vaccination program has led to a substantial reduction in childhood meningitis and bacteraemia, highlighting its public health success.

    More Related Videos

    Experimental Human Pneumococcal Carriage07:47

    Experimental Human Pneumococcal Carriage

    Published on: February 15, 2013

    Related Concept Videos

    Pneumonia V: Nursing management and Prevention01:30

    Pneumonia V: Nursing management and Prevention

    Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
    The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
    Enhance airway patency
    Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
    Respiratory Syncytial Virus Disease01:29

    Respiratory Syncytial Virus Disease

    Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    Poliomyelitis01:17

    Poliomyelitis

    Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
    Pneumonia III: Complications and Assessment01:30

    Pneumonia III: Complications and Assessment

    Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: